Autoinflammation 2013: The Seventh International Congress of FMF and Autoinflammatory Diseases Wednesday, May 22, 2013 -
Sunday, May 26, 2013
Location: Lausanne, Switzerland Description: The goals of this meeting include the exchange of clinical and scientific information regarding the autoinflammatory diseases. This is likely to result in improvements in the diagnosis and treatment of these diseases. Past Congresses have resulted in new scientific collaborations, development of registries for patients with specific autoinflammatory disorders, and the initiation of multicenter clinical trials.
AIP has two distinct subtypes, which are primarily defined by their pathologic features. The subtypes have different clinical profiles, disease manifestations, and clinical outcomes. Type 2 AIP is histologically defined by the presence of GELs and the lack of abundant IgG4-positive staining plasma cells. Patients with type 2 AIP tend to be younger at the time of diagnosis and the gender distribution is more equal than in type 1 AIP. Unlike type 1 AIP, which is recognized as part of systemic IgG4-related disease, type 2 AIP is an isolated pancreatic disorder. Aside from the frequent association with inflammatory bowel disease there are no characteristic other organ involvement. The disease manifestations of type 2 AIP are extremely sensitive to steroid therapy, and disease relapses are exceedingly uncommon.